Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
PH-894: Potent and Specific Silencing of BRD4 in NK CellsMarlborough, Massachusetts--( - October 16, 2024) - Phio ...
The American Journal of Managed Care4h
Lipopolymer-Delivered RNA Interference Shows Promise Against FLT3-Mutated AML
Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...
eLife22h
Loss function of tumor suppressor FRMD8 confers resistance to tamoxifen therapy via a dual mechanism
Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences; Peking University International Cancer Institute; and State Key Laboratory ...
eLife1d
Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer
The work presented will be of interest to cancer biologists and more broadly to those interested in NSCLC translational studies. Non-small cell lung cancer (NSCLC) is the most common subtype of lung ...